Findings from this comparative study indicate a favorable failure-free survival and progression-free survival with Standard of Care plus abiraterone acetate and prednisone.
In a study, the risk for heart failure was 81% higher among patients who received androgen deprivation therapy.
63% of patients were managed initially with observation.
Men with PSA values of 2.5 ng/mL or less and Gleason 8 to 10 prostate tumors are at higher risk of death than other high-risk PCa patients.
The 3-year overall survival rate among prostate cancer patients starting long-term hormone therapy was 83% vs 76% for men receiving abiraterone plus ADT vs ADT alone.
Only luminal B prostate cancers were significantly associated with postoperative response to ADT in a subset analysis in retrospective cohorts.
Combined treatment for recurrent prostate cancer after radical prostatectomy results in decreased long-term all-cause and cancer-specific mortality.
During a median followup of 3.6 and 3.0 years intravesical recurrence developed in 4 (12.5%) and 59 men (30.1%) with and without androgen suppression therapy, respectively.
No increased risk of dementia for androgen deprivation therapy use versus nonuse.
Patient motivation is pivotal to the success of exercise interventions, researchers noted.
The risk of dementia was 2-fold higher among ADT users.
Study tested the combination in men with treatment-naïve prostate cancer and bone metastasis.
Ongoing use of androgen-deprivation therapy (ADT) for up to 36 months is not associated with cognitive decline among men with prostate cancer.
Men with 1 or 2 copies of the HSD3B1 (1245C) allele are more likely to experience disease progression.
Prostatectomy and radiotherapy with or without ADT reduced prostate cancer-specific and all-cause mortality rates.
Androgen deprivation increased all-cause mortality risk by 77% among black men who underwent brachytherapy for favorable-risk prostate cancer.
Superior median, 5-year OS for prostate RT plus ADT versus ADT alone in propensity score analyses.
Radiation therapy also is associated with a greater likelihood of fractures.
Adding short-term androgen suppression to salvage radiotherapy may benefit men with prostate cancer who have undergone radical prostatectomy.
New findings show metabolic changes suggesting that a carbohydrate-restricted diet may improve insulin sensitivity.
Researchers find 23% increased risk compared to men who received other treatments.
Adding bevacizumab to androgen deprivation therapy (ADT) resulted in improved relapse-free survival in patients with hormone-sensitive prostate cancer.
The advice is useful as clinicians wait for formal guidelines.
Combined radiotherapy remains controversial due to the increased potential for toxicities.
Anti-androgen therapy during and after salvage radiotherapy in patients with localized prostate cancer significantly improved long-term overall survival.
The finding of lower bladder cancer incidence in patients receiving pelvic radiation contrasts with previous research.
In a small study, high-dose testosterone given intermittently with androgen deprivation therapy lowered PSA levels without serious adverse effects.
A 12-gene androgen deprivation therapy resistance signature may help guide therapeutic decision making after radical prostatectomy.
Higher risks of several clinically relevant adverse effects compared with surgical castration.
The study found no association with obesity, however, unlike previous studies.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)